BACKGROUND: Treatment recommendations have been developed for management of
patients with chronic myeloid leukemia (CML). METHODS: A 30‐item multiple‐choice …

BACKGROUND. The success of imatinib therapy for chronic myeloid leukemia (CML) has
brought new challenges; these include optimizing disease monitoring, imatinib resistance …

Background With the advent of tyrosine kinase inhibitors (TKIs), the prognosis of chronic
myeloid leukemia (CML) has undergone significant changes in all age groups and at …

To determine potential predictors of long‐term survival in a large set of Hispanic (Mexican)
patients with chronic myeloid leukemia (CML) treated with imatinib. We conducted an …

A total of 1569 patients with chronic myeloid leukemia (CML) referred to our institution within
1 month of diagnosis since 1965 were reviewed: 1148 chronic phase (CP), 175 accelerated …

BACKGROUND There is paucity of data from developing countries on the efficacy and safety
of imatinib mesylate in chronic myeloid leukemia (CML). The primary objective of this study …

Introduction: The arrival of targeted therapy for chronic myeloid leukemia (CML) was
revolutionary. However, due to the high cost of tyrosine kinase inhibitors, access to this …

Purpose: The BCR-ABL tyrosine kinase inhibitor imatinib has dramatically improved the
prognosis for most patients with chronic myeloid leukemia (CML). Efforts to optimize therapy …

Chronic myeloid leukemia (cml) is a myeloproliferative disorder whose therapy has changed
dramatically since the late 1990s. With the introduction of the tyrosine kinase inhibitor (tki) …

Background Few studies have examined the longitudinal changes in the patterns, selection,
and utilization of treatments for chronic myeloid leukemia (CML) in routine clinical practice …